TGFB1 and neoplasm: Targeting TGF-β could weaken both the expression of CXCR4 and activation of TβR–Smad signaling in stromal fibroblasts, thus hindering the feedback loop of TGF-β and SDF-1 and blocking the activation of tumor-promoting CAFs [37].